and i am officially diagnosed with secondary immunodeficiency, so i can f#ck myself up doing what you doin now - thanx for enlightening Hip
Possibly yes, possibly not.
The
study you quoted above refers to the effect of purified staphylococcal toxoid on the secondary immunodeficiency that appears
during coxsackievirus B infection.
The study found that this secondary immunodeficiency can be improved or worsened, depending on the scheme of administration of purified staphylococcal toxoid. To quote the study:
Depending on the scheme of the experiment, purified staphylococcal toxoid normalized the defects of immune response to sheep red blood cells or poliovirus, increased suppression or showed no activity.
The
other study by Dr Irina Semenova that you cited above also says the same thing:
It is proved that the result immunocorrective effect of Licopid and purified staphylococcal toxoid are dose-dependent, and depend on the scheme of administration, as well as the genotype of experimental animals (mice).
The dose dependency could be important. It seems that some dose levels improve the secondary immunodeficiency, and some worsen it.
Interestingly, Dr Semenova used staphylococcal toxoid in combination with an anti-inflammatory treatment:
Purified staphylococcal toxoid within an integrated anti-inflammatory therapy of acute inflammatory diseases of the uterus associated with different combinations of opportunistic and pathogenic bacteria, corrects various immunological disorders: normalizes the number of T-lymphocytes
Note that this is an animal study, so the results may not apply to humans. Although Dr Semenova does say this:
The direct correlation between the test results of purified staphylococcal toxoid or Licopid in animal studies with secondary immunodeficiency, and data obtained from the use of these drugs in the clinic, gives reason to recommend mice bred to have induced immunosuppression as a model.
So in other words, Dr Semenova's results from testing purified staphylococcal toxoid or Licopid on mice correlated well with her results testing these drugs on humans in a clinical setting.
It would be nice to contact Dr Semenova, in order to get some information on these schemes of administration and dose levels, and to learn which schemes and doses improved the CVB secondary immunodeficiency, and which schemes worsened it.
Perhaps you can add this question in the email that you send Dr Semenova.
But whether your secondary immunodeficiency is caused by coxsackievirus B or some other cause, we do not know. The immunodeficiency caused by coxsackievirus B only occurs in the first few months of infection, according to
research performed by Dr John Chia. Chia found that the CD8 lymphocyte counts can drop dramatically in the first few months of CVB infection, before returning back to normal. This immunodeficiency tends to cause varicella zoster virus outbreaks, in the form of shingles on the skin. But this CVB immunodeficiency only lasts a few months.
So if you have long-standing secondary immunodeficiency, it may be due to some other factor.
My guess is that Dr Semenova's studies are looking at acute CVB infections (within the first month or two of infection), not long term chronic CVB infections.
Note as well that this correction (or worsening) of any acute CVB-induced secondary immunodeficiency by purified staphylococcal toxoid (assumed to be alpha toxin toxoid) may or may not be related to any benefits this toxoid has for ME/CFS.
It is worth repeating here what I
said earlier:
Note that this Russian product may be a slightly different formulation to Staphypan®, and as such, is a product not previously tested on ME/CFS patients. Thus there is an inherent risk to taking this Russian vaccine, and anyone doing so needs to understand that this is an experimental treatment, which may not work, and may have significant risks or side effects.
By the way, the Russian drug cycloferon (циклоферон), which some people on this forum found helpful for ME/CFS, is good for treating secondary immunodeficiency associated with chronic bacterial and fungal
infections.
